Journey Medical (NASDAQ:DERM) vs. Dyne Therapeutics (NASDAQ:DYN) Head to Head Analysis

Dyne Therapeutics (NASDAQ:DYN) and Journey Medical (NASDAQ:DERM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Institutional & Insider Ownership

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by insiders. Comparatively, 15.0% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Dyne Therapeutics and Journey Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.12%	-56.75%
Journey Medical	-14.58%	-39.94%	-10.45%

Volatility and Risk

Dyne Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Valuation & Earnings

This table compares Dyne Therapeutics and Journey Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$317.42 million	($3.66)	-5.70
Journey Medical	$56.13 million	3.58	-$14.67 million	($0.35)	-21.84

Journey Medical has higher revenue and earnings than Dyne Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Dyne Therapeutics and Journey Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	3	10	4	2.94
Journey Medical	1	1	3	0	2.40

Dyne Therapeutics currently has a consensus target price of $34.93, suggesting a potential upside of 67.58%. Journey Medical has a consensus target price of $12.17, suggesting a potential upside of 59.15%. Given Dyne Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Journey Medical.

Summary

Dyne Therapeutics beats Journey Medical on 8 of the 14 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.